182 results match your criteria patients bnt162b2

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.

ACR Open Rheumatol 2021 Jul 17. Epub 2021 Jul 17.

Aarhus University Hospital, Aarhus, Denmark.

Objective: With a vaccine effectiveness of 95% for preventing coronavirus disease 2019 (COVID-19), Pfizer-BioNTech BNT162b2 (BNT162b2) was the first vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be approved. However, immunosuppressive therapy was an exclusion criterion in the phase 3 trial that led to approval. Thus, extrapolation of the trial results to patients with rheumatic diseases treated with immunosuppressive drugs warrants caution. Read More

View Article and Full-Text PDF

Comparison of BNT162b2 (BioNTech/Pfizer) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.

Kidney Int 2021 Jul 13. Epub 2021 Jul 13.

Department of Medicine III-Nephrology, Hypertension, Transplantation, Rheumatology, Geriatrics, Ordensklinikum Linz-Elisabethinen Hospital, Linz, Austria. Electronic address:

View Article and Full-Text PDF

Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections.

medRxiv 2021 Jul 12. Epub 2021 Jul 12.

Importance: Vaccine breakthrough by an emergent SARS-CoV-2 variant poses a great risk to global public health.

Objective: To determine the SARS-CoV-2 variant responsible for 6 cases of vaccine breakthrough.

Design: Nasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Read More

View Article and Full-Text PDF

SARS-CoV-2 Infections in mRNA Vaccinated Individuals are Biased for Viruses Encoding Spike E484K and Associated with Reduced Infectious Virus Loads that Correlate with Respiratory Antiviral IgG levels.

medRxiv 2021 Jul 7. Epub 2021 Jul 7.

Introduction: COVID-19 large scale immunization in the US has been associated with infrequent breakthrough positive molecular testing. Whether a positive test is associated with a high viral RNA load, specific viral variant, recovery of infectious virus, or symptomatic infection is largely not known.

Methods: In this study, we identified 133 SARS-CoV-2 positive patients who had received two doses of either Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) vaccines, the 2nd of which was received between January and April of 2021. Read More

View Article and Full-Text PDF

Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2.

Kidney Int 2021 Jul 12. Epub 2021 Jul 12.

Department of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany; German Center for Infection Research, Heidelberg partner site, Heidelberg, Germany; Division Virus-Associated Carcinogenesis, German Cancer Research Center, Heidelberg, Germany.

View Article and Full-Text PDF

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.

Lancet Rheumatol 2021 Jul 8. Epub 2021 Jul 8.

St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, UK.

Background: Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses to COVID-19 vaccine BNT162b2 (Pfizer-BioNTech) in patients taking methotrexate and commonly used targeted biological therapies, compared with healthy controls. Given the roll-out of extended interval vaccination programmes to maximise population coverage, we present findings after the first dose. Read More

View Article and Full-Text PDF

Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.

JAMA Intern Med 2021 Jul 13. Epub 2021 Jul 13.

Department of Health Behavior and Policy, Virginia Commonwealth University, Richmond.

Importance: Two mRNA-based vaccines against coronavirus disease 2019 (COVID-19) were found to be highly efficacious in phase 3 clinical trials in the US. However, patients with chronic illnesses, including cirrhosis, were excluded from clinical trials. Patients with cirrhosis have immune dysregulation that is associated with vaccine hyporesponsiveness. Read More

View Article and Full-Text PDF

Emergency Department Utilization by In-hospital Healthcare Workers after COVID-19 Vaccination.

J Korean Med Sci 2021 Jul 12;36(27):e196. Epub 2021 Jul 12.

Department of Emergency Medicine, Ajou University School of Medicine, Suwon, Korea.

Background: This is an observational study to analyze an emergency department (ED) utilization pattern of coronavirus disease 2019 (COVID-19) vaccinated in-hospital healthcare workers (HCWs).

Methods: We included 4,703 HCWs who were administered the first dose of the COVID-19 vaccine between March 4 and April 2, 2021, in a tertiary hospital in Korea where fast-track and post-vaccination cohort zone (PVCZ) were introduced in ED. We analyzed data of participants' age, sex, occupation, date and type of vaccination, and their clinical information using SPSS v25. Read More

View Article and Full-Text PDF

Cutaneous reactions after SARS-COV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases.

Br J Dermatol 2021 Jul 13. Epub 2021 Jul 13.

Servicio de Dermatología. Hospital Universitario de Toledo, Toledo, Spain.

Background: Cutaneous reactions after SARS-CoV-2 vaccines are poorly characterized.

Objectives: The primary objective was to describe and classify cutaneous reactions after SARS-CoV-2 vaccination.

Methods: A nationwide Spanish cross-sectional study was conducted. Read More

View Article and Full-Text PDF

Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.

JAMA 2021 Jul 12. Epub 2021 Jul 12.

Primary Health Division, Maccabi Healthcare Services, Tel Aviv, Israel.

Importance: Data on BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) effectiveness and safety in pregnancy are currently lacking because pregnant women were excluded from the phase 3 trial.

Objective: To assess the association between receipt of BNT162b2 mRNA vaccine and risk of SARS-CoV-2 infection among pregnant women.

Design, Setting, And Participants: This was a retrospective cohort study within the pregnancy registry of a large state-mandated health care organization in Israel. Read More

View Article and Full-Text PDF

A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?

Rashed Noor

Curr Clin Microbiol Rep 2021 Jul 3:1-8. Epub 2021 Jul 3.

Department of Life Sciences (DLS), School of Environment and Life Sciences (SELS), Independent University, Bangladesh (IUB), Plot 16, Block B, Aftabuddin Ahmed Road, Bashundhara, Dhaka, 1229 Bangladesh.

Purpose Of Review: In order to eradicate the COVID-19 pandemic, scientists around the world have been working very hard for a year or more with the motto of designing effective drugs and vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2). Along with the positive results with the antiviral drugs and a few commercialized vaccines, the unresponsiveness as well as some side effects of such therapies have also been noticed, possibly due to the emergence of the SARS-CoV-2 variants. Therefore, current review summarized the actual effectiveness of the antivirals and vaccines which are in current use for the treatment of the COVID-19 patients. Read More

View Article and Full-Text PDF

Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study.

Thromb Res 2021 Jun 25;205:24-28. Epub 2021 Jun 25.

Department of Medicine, General Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, University of Padua Medical School, Padua, Italy. Electronic address:

Background: It is still unknown whether COVID-19 vaccines induce a prothrombotic state or increase the hypercoagulable condition in subjects with a predisposition to thrombosis.

Objectives: We evaluated the coagulation profile in a series of healthy subjects who received the first dose of the BNT162b2 or the ChAdOx1 vaccines and assessed whether hypercoagulability developed.

Patients/methods: Volunteers among the staff of the University of Padua or health care professionals in the Padua University Hospital who had received either the ChAdOx1 or BNT162b2 vaccine in the previous 10 ± 2 days were eligible. Read More

View Article and Full-Text PDF

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.

Clin Microbiol Infect 2021 Jul 7. Epub 2021 Jul 7.

School of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Shaare Zedek Medical Centre, Jerusalem, Israel.

Objectives: The mRNA coronavirus disease 2019 (COVID-19) vaccines have shown high effectiveness in the prevention of symptomatic COVID-19, hospitalization, severe disease and death. Nevertheless, a minority of vaccinated individuals might become infected and experience significant morbidity. Characteristics of vaccine breakthrough infections have not been studied. Read More

View Article and Full-Text PDF

Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies.

Inflammopharmacology 2021 Aug 9;29(4):1075-1090. Epub 2021 Jul 9.

School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom.

This paper aims to summarize through meta-analyses the overall vaccine effectiveness of the BNT162b2 mRNA vaccine from observational studies. A systematic literature search with no language restriction was performed in electronic databases to identify eligible observational studies which reported the adjusted effectiveness of the BNT162b2 mRNA vaccine to prevent RT-PCR confirmed COVID-19. Meta-analyses with the random-effects model were used to calculate the pooled hazard ratio (HR) and pooled incidence rate ratio (IRR) at 95% confidence intervals, and the vaccine effectiveness was indicated as (pooled HR - 1)/HR or (pooled IRR - 1)/IRR. Read More

View Article and Full-Text PDF

Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.

Clin Res Cardiol 2021 Aug 9;110(8):1142-1149. Epub 2021 Jul 9.

Klinik für Thorax- und Kardiovaskularchirurgie, Herz und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.

Aims: Immunocompromised patients have been excluded from studies of SARS-CoV-2 messenger RNA vaccines. The immune response to vaccines against other infectious agents has been shown to be blunted in such patients. We aimed to analyse the humoral and cellular response to prime-boost vaccination with the BNT162b2 vaccine (Pfizer-BioNTech) in cardiothoracic transplant recipients. Read More

View Article and Full-Text PDF

Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.

JAMA Oncol 2021 Jul 8. Epub 2021 Jul 8.

Division of Oncology, Rambam Health Care Campus, Haifa, Israel.

Importance: The efficacy and safety profile of SARS-CoV-2 vaccines have been acquired from phase 3 studies; however, patients with cancer were not represented in these trials. Owing to the recommendation to prioritize high-risk populations for vaccination, further data are warranted.

Objective: To evaluate the use and safety of the BNT162b2 vaccine in patients undergoing treatment for cancer. Read More

View Article and Full-Text PDF

The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience.

Eur J Cancer 2021 Jun 23;154:30-34. Epub 2021 Jun 23.

Department of Pediatric Immunology, Hematology and Oncology, Children Hospital of La Timone, AP-HM, Marseille, France; SMARTc Unit, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix Marseille Univ, Marseille France. Electronic address:

Background And Aims: COVID-19 infection in paediatric patients with cancer is severe or critical in 20% of the patients. It can therefore directly affect paediatric patients with cancer and/or their care. We aimed at evaluating the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults (AYA) with solid tumour. Read More

View Article and Full-Text PDF

Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients.

EJHaem 2021 Jun 1. Epub 2021 Jun 1.

Department of Hematology Nantes University Hospital Nantes France.

This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer-BioNTech) in 112 Allo-HSCT patients. Antibody response to SARS-CoV-2 spike protein receptor-binding domain was tested at the time of the second injection (Roche Elecsys). The study also included a non-randomized control arm of 26 healthy controls. Read More

View Article and Full-Text PDF

Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders.

J Allergy Clin Immunol Pract 2021 Jul 2. Epub 2021 Jul 2.

Allergy and Clinical Immunology Unit, Meir General Hospital, Kfar-Saba, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

View Article and Full-Text PDF

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.

Lancet Haematol 2021 Aug 2;8(8):e583-e592. Epub 2021 Jul 2.

Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Background: Haematological malignancies and their treatments are likely to affect SARS-CoV-2 vaccine efficacy. We aimed to evaluate serological response to BNT162b2 vaccine in patients with haematological malignancies by type of treatment.

Methods: Our national prospective cohort study was done in Lithuania and assessed serological response to one and two BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine doses in healthy health-care workers and in patients with haematological malignancies. Read More

View Article and Full-Text PDF

Acute myocarditis associated with anti-COVID-19 vaccination.

Alon Nevet

Clin Exp Vaccine Res 2021 May 31;10(2):196-197. Epub 2021 May 31.

Hillel Yaffe Medical Center, Hadera, Israel.

Novel anti-coronavirus disease 2019 mRNA vaccines are rapidly implemented worldwide. Therefore, attention should be given to potentially life-threatening adverse reactions. We report on three young male patients, who developed acute myocarditis 2 days after receiving the second dose of the BNT162b2 vaccine. Read More

View Article and Full-Text PDF

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.

Front Immunol 2021;12:704773. Epub 2021 Jun 16.

Department of Internal Medicine 3 (Nephrology and Dialysis), Feldkirch Academic Teaching Hospital, Feldkirch, Austria.

Background: Hemodialysis patients are at high risk for severe COVID-19. SARS-CoV-2 vaccination related safety and immunogenicity data in these patients are rare.

Methods: In this observational study SARS-CoV-2-seronegative hemodialysis patients were vaccinated with two doses of the Pfizer/BioNTech mRNA-BNT162b2 vaccine (COMIRNATY 30 µg) and followed for 90 days. Read More

View Article and Full-Text PDF

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis.

Kidney Int 2021 Jun 30. Epub 2021 Jun 30.

Department of Nephrology, Dialysis, and Renal Transplantation, Centre Hospitalo-Universitaire Besançon, Besançon, France; Federation Hospitalo-Universitaire INCREASE, Besançon, France.

View Article and Full-Text PDF

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.

Transplant Cell Ther 2021 Jun 30. Epub 2021 Jun 30.

Bone Marrow Transplantation Unit, Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel; Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Data are scarce regarding both the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing immune cell therapy; thus, we prospectively evaluated these two domains in patients receiving this vaccine after allogeneic hematopoietic cell transplantation (HCT; n = 66) or after CD19-based chimeric antigen receptor T cell (CART) therapy (n = 14). Overall, the vaccine was well tolerated, with mild non-hematologic vaccine-reported adverse events in a minority of the patients. Twelve percent of the patients after the first dose and 10% of the patients after the second dose developed cytopenia, and there were three cases of graft-versus-host disease exacerbation after each dose. Read More

View Article and Full-Text PDF

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.

Cancer Cell 2021 Jun 18. Epub 2021 Jun 18.

Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA. Electronic address:

Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Read More

View Article and Full-Text PDF

Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study.

Vaccine 2021 07 23;39(32):4410-4413. Epub 2021 Jun 23.

CHU de Caen, Departments of Biostatistics and Clinical Research, Avenue de la Côte de Nacre, Caen F-14000, France; Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université Caen Normandie, Caen F-14000, France.

Introduction: Studies evaluating BNT162b2 mRNA Covid-19 vaccine safety excluded subjects with a previous history of COVID-19 infection. The aim of our study was to focus on the tolerance of this vaccine this population.

Methods: An anonymous self-reporting survey related to safety and tolerance of vaccine was completed by subjects 21 to 28 days after the first vaccine dose in two vaccination centers. Read More

View Article and Full-Text PDF

Evaluation of SARS-CoV-2 Spike Protein Antibody Titers in Cord Blood after COVID-19 Vaccination during Pregnancy in Polish Healthcare Workers: Preliminary Results.

Vaccines (Basel) 2021 Jun 19;9(6). Epub 2021 Jun 19.

Department of Gynaecology and Obstetrics, Gynaecological Oncology Clinical Ward, Regional Specialist Hospital, ul. Żołnierska 18, 10-561 Olsztyn, Poland.

Background: The coronavirus disease 2019 (COVID-19) pandemic has given rise to the need to develop a vaccine as quickly as possible. As pregnant women are at increased risk of contracting severe COVID-19, with higher mortality, it is essential to assess the safety of the vaccines administered during pregnancy.

Methods: The aim of this study was to determine the titer of specific maternal and cord antibodies against severe acute respiratory syndrome coronavirus 2 S protein after antenatal vaccination. Read More

View Article and Full-Text PDF

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.

Vaccines (Basel) 2021 Jun 8;9(6). Epub 2021 Jun 8.

National Institute for Infectious Diseases Lazzaro Spallanzani, 00149 Rome, Italy.

Vaccination against SARS-CoV-2 is considered the most effective method of prevention to contain the pandemic. While highly effective SARS-CoV-2 vaccines are being applied on a large-scale, whether and to what extent the strength of the vaccine-induced immune response could be further potentiated is still an object of debate. Several reports studied the effect of different vaccines on the susceptibility and mortality of COVID-19, with conflicting results. Read More

View Article and Full-Text PDF